Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 59 | 2023 | 3054 | 5.260 |
Why?
|
| Magnetic Resonance Imaging | 44 | 2023 | 3516 | 4.070 |
Why?
|
| Contrast Media | 35 | 2023 | 1076 | 2.150 |
Why?
|
| Lymph Nodes | 8 | 2021 | 552 | 2.130 |
Why?
|
| Axilla | 11 | 2021 | 104 | 1.970 |
Why?
|
| Lymphatic Metastasis | 11 | 2017 | 498 | 1.910 |
Why?
|
| Ultrasonography, Mammary | 7 | 2013 | 81 | 1.650 |
Why?
|
| Carcinoma, Ductal, Breast | 6 | 2021 | 160 | 1.460 |
Why?
|
| Image Interpretation, Computer-Assisted | 14 | 2018 | 693 | 1.360 |
Why?
|
| Breast | 13 | 2022 | 289 | 1.280 |
Why?
|
| Image Enhancement | 13 | 2021 | 562 | 1.280 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 13 | 2020 | 471 | 1.180 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 5 | 2021 | 118 | 1.160 |
Why?
|
| Gadolinium DTPA | 13 | 2015 | 255 | 1.130 |
Why?
|
| Sensitivity and Specificity | 26 | 2023 | 2008 | 0.950 |
Why?
|
| Receptor, ErbB-2 | 6 | 2023 | 259 | 0.890 |
Why?
|
| ROC Curve | 19 | 2015 | 786 | 0.860 |
Why?
|
| Mammography | 9 | 2021 | 471 | 0.830 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 5 | 2022 | 295 | 0.810 |
Why?
|
| Radiologists | 1 | 2021 | 51 | 0.680 |
Why?
|
| Biopsy | 13 | 2022 | 1194 | 0.680 |
Why?
|
| Middle Aged | 50 | 2023 | 27053 | 0.670 |
Why?
|
| Female | 66 | 2023 | 47906 | 0.670 |
Why?
|
| Radiography, Thoracic | 9 | 2006 | 331 | 0.660 |
Why?
|
| Diagnosis, Differential | 20 | 2022 | 1593 | 0.660 |
Why?
|
| Aged | 39 | 2023 | 19950 | 0.640 |
Why?
|
| Diagnosis, Computer-Assisted | 7 | 2011 | 334 | 0.620 |
Why?
|
| Adult | 41 | 2023 | 27553 | 0.600 |
Why?
|
| Biopsy, Needle | 3 | 2010 | 229 | 0.570 |
Why?
|
| Mass Screening | 6 | 2018 | 675 | 0.570 |
Why?
|
| Neoadjuvant Therapy | 7 | 2023 | 400 | 0.550 |
Why?
|
| Humans | 82 | 2023 | 92353 | 0.550 |
Why?
|
| Kinetics | 9 | 2023 | 1552 | 0.540 |
Why?
|
| Retrospective Studies | 26 | 2023 | 9693 | 0.530 |
Why?
|
| Aged, 80 and over | 19 | 2020 | 6919 | 0.460 |
Why?
|
| Observer Variation | 14 | 2020 | 612 | 0.430 |
Why?
|
| User-Computer Interface | 3 | 2012 | 188 | 0.420 |
Why?
|
| Ultrasonography, Interventional | 2 | 2013 | 121 | 0.380 |
Why?
|
| Diagnostic Imaging | 2 | 2013 | 461 | 0.370 |
Why?
|
| Lung Diseases, Interstitial | 4 | 2005 | 281 | 0.350 |
Why?
|
| Organometallic Compounds | 3 | 2016 | 141 | 0.330 |
Why?
|
| Lung Neoplasms | 11 | 2008 | 2394 | 0.330 |
Why?
|
| Neoplasm Staging | 8 | 2018 | 2032 | 0.320 |
Why?
|
| Tomography, Spiral Computed | 3 | 2004 | 77 | 0.320 |
Why?
|
| Carcinoma | 1 | 2013 | 438 | 0.320 |
Why?
|
| Lung Diseases | 4 | 2004 | 283 | 0.290 |
Why?
|
| Decision Making | 1 | 2013 | 680 | 0.280 |
Why?
|
| Solitary Pulmonary Nodule | 7 | 2006 | 139 | 0.280 |
Why?
|
| Reproducibility of Results | 13 | 2018 | 2794 | 0.270 |
Why?
|
| Mastectomy, Segmental | 2 | 2021 | 101 | 0.260 |
Why?
|
| Ultrasonography | 3 | 2017 | 708 | 0.260 |
Why?
|
| Prospective Studies | 10 | 2022 | 4474 | 0.240 |
Why?
|
| Young Adult | 8 | 2021 | 6624 | 0.240 |
Why?
|
| Meglumine | 2 | 2016 | 38 | 0.230 |
Why?
|
| Pattern Recognition, Automated | 4 | 2011 | 222 | 0.230 |
Why?
|
| Calcinosis | 4 | 2011 | 230 | 0.230 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2021 | 485 | 0.230 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2017 | 1271 | 0.220 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 357 | 0.210 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2016 | 607 | 0.210 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2017 | 80 | 0.210 |
Why?
|
| Breast Density | 2 | 2020 | 35 | 0.200 |
Why?
|
| Preoperative Care | 2 | 2016 | 405 | 0.190 |
Why?
|
| Incidental Findings | 2 | 2013 | 98 | 0.180 |
Why?
|
| Algorithms | 8 | 2017 | 1961 | 0.170 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2020 | 39 | 0.170 |
Why?
|
| Reference Standards | 1 | 2021 | 142 | 0.170 |
Why?
|
| Radiographic Image Enhancement | 4 | 2009 | 465 | 0.160 |
Why?
|
| Prognosis | 3 | 2013 | 3871 | 0.160 |
Why?
|
| Fibroadenoma | 1 | 2019 | 9 | 0.160 |
Why?
|
| Peptide Fragments | 1 | 2020 | 465 | 0.150 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 285 | 0.140 |
Why?
|
| Microvessels | 1 | 2018 | 71 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2005 | 2685 | 0.140 |
Why?
|
| Computer Simulation | 3 | 2015 | 1112 | 0.140 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1118 | 0.140 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 207 | 0.130 |
Why?
|
| Subtraction Technique | 3 | 2006 | 130 | 0.130 |
Why?
|
| Clinical Competence | 3 | 2009 | 809 | 0.130 |
Why?
|
| Information Storage and Retrieval | 3 | 2013 | 123 | 0.130 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2018 | 105 | 0.130 |
Why?
|
| False Negative Reactions | 2 | 2013 | 63 | 0.130 |
Why?
|
| Fourier Analysis | 1 | 2016 | 128 | 0.120 |
Why?
|
| Early Detection of Cancer | 2 | 2018 | 470 | 0.120 |
Why?
|
| Adipose Tissue | 2 | 2008 | 266 | 0.120 |
Why?
|
| Area Under Curve | 5 | 2018 | 337 | 0.120 |
Why?
|
| Metabolic Clearance Rate | 1 | 2015 | 118 | 0.120 |
Why?
|
| Radiography | 3 | 2012 | 794 | 0.120 |
Why?
|
| Support Vector Machine | 1 | 2013 | 23 | 0.100 |
Why?
|
| Signal-To-Noise Ratio | 3 | 2019 | 110 | 0.100 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2013 | 34 | 0.100 |
Why?
|
| Genomics | 1 | 2019 | 806 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1480 | 0.100 |
Why?
|
| Radiology Information Systems | 1 | 2013 | 78 | 0.100 |
Why?
|
| Medical Records | 1 | 2013 | 122 | 0.100 |
Why?
|
| Models, Theoretical | 3 | 2018 | 497 | 0.100 |
Why?
|
| Phenotype | 2 | 2019 | 2503 | 0.100 |
Why?
|
| Breast Diseases | 2 | 2011 | 101 | 0.090 |
Why?
|
| Echo-Planar Imaging | 2 | 2017 | 52 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 1761 | 0.090 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 107 | 0.090 |
Why?
|
| Postoperative Period | 1 | 2012 | 311 | 0.090 |
Why?
|
| Lymph Node Excision | 2 | 2013 | 225 | 0.090 |
Why?
|
| Illinois | 1 | 2013 | 502 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2015 | 425 | 0.080 |
Why?
|
| Prevalence | 2 | 2013 | 1297 | 0.080 |
Why?
|
| Models, Biological | 2 | 2015 | 1784 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2018 | 2368 | 0.080 |
Why?
|
| False Positive Reactions | 3 | 2005 | 220 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 1398 | 0.080 |
Why?
|
| Computer Terminals | 1 | 2009 | 7 | 0.080 |
Why?
|
| Adolescent | 2 | 2019 | 9493 | 0.080 |
Why?
|
| Carcinoma, Ductal | 1 | 2008 | 18 | 0.070 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2008 | 40 | 0.070 |
Why?
|
| Carcinoma, Lobular | 1 | 2008 | 81 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2017 | 800 | 0.070 |
Why?
|
| Artifacts | 2 | 2018 | 246 | 0.070 |
Why?
|
| Ribs | 1 | 2006 | 47 | 0.060 |
Why?
|
| Radiology | 2 | 2008 | 205 | 0.060 |
Why?
|
| Risk Factors | 2 | 2014 | 5706 | 0.060 |
Why?
|
| Lung | 4 | 2005 | 1338 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2023 | 8729 | 0.050 |
Why?
|
| Radiology, Interventional | 1 | 2004 | 63 | 0.050 |
Why?
|
| Neoplasms | 1 | 2018 | 3123 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2004 | 1899 | 0.050 |
Why?
|
| Intracranial Aneurysm | 1 | 2004 | 200 | 0.050 |
Why?
|
| Quality Control | 2 | 2018 | 118 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2022 | 35 | 0.050 |
Why?
|
| Hormones | 1 | 2022 | 141 | 0.050 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2004 | 273 | 0.050 |
Why?
|
| Male | 8 | 2020 | 43932 | 0.040 |
Why?
|
| Machine Learning | 1 | 2023 | 303 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2015 | 901 | 0.040 |
Why?
|
| Stomach | 1 | 2020 | 111 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2022 | 1178 | 0.040 |
Why?
|
| Smoking | 1 | 2003 | 639 | 0.040 |
Why?
|
| Gadolinium | 1 | 2019 | 104 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 183 | 0.040 |
Why?
|
| Electric Conductivity | 1 | 2018 | 145 | 0.040 |
Why?
|
| Radiation Dosage | 3 | 2004 | 229 | 0.040 |
Why?
|
| Stomach Neoplasms | 1 | 2020 | 296 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 226 | 0.030 |
Why?
|
| Time | 1 | 2016 | 79 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1772 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1938 | 0.030 |
Why?
|
| Entropy | 1 | 2015 | 42 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2980 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 305 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1150 | 0.030 |
Why?
|
| Diagnostic Errors | 2 | 2005 | 158 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2013 | 105 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2014 | 179 | 0.020 |
Why?
|
| Apoptosis | 1 | 2019 | 1737 | 0.020 |
Why?
|
| Software | 1 | 2017 | 677 | 0.020 |
Why?
|
| Adenocarcinoma | 3 | 2004 | 1190 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1573 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 2555 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 401 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 1847 | 0.020 |
Why?
|
| Fats | 1 | 2011 | 12 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 569 | 0.020 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2014 | 177 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 899 | 0.020 |
Why?
|
| Injections | 1 | 2010 | 119 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 410 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 2397 | 0.020 |
Why?
|
| Liquid Crystals | 1 | 2009 | 12 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 219 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 4213 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2006 | 376 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2004 | 152 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 1 | 2004 | 137 | 0.010 |
Why?
|
| Japan | 1 | 2003 | 306 | 0.010 |
Why?
|
| Time Factors | 1 | 2008 | 5429 | 0.010 |
Why?
|
| Incidence | 1 | 2003 | 1661 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 1090 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 3776 | 0.010 |
Why?
|